



Targeting Tumor Microenvironment in Cancer: Promises and Challenges

Guest Editors:

Prof. Dr. Ahmed H.K. El-Hashash

Biology Department, Texas A&M University, Houston, TX 77030, USA

Prof. Dr. Hussein Sabit

Department of Medical Biotechnology, College of Biotechnology, Misr University for Science and Technology, Giza P.O. Box 77, Egypt

Dr. Borros Michael Arneth

Institut für Laboratoriumsmedizin und Pathobiochemie, Molekulare Diagnostik, Universitätsklinikum Gießen und Marburg GmbH, 35392 Gießen, Germany

Deadline for manuscript submissions:

20 July 2024

Message from the Guest Editors

Dear Colleagues,

The tumor microenvironment (TME) is the environment surrounding a tumor, and it plays a critical role in cancer progression. The TME is made up of a variety of cells, including tumor cells, immune cells, and stromal cells. These cells interact with each other in a complex way to create an environment that is favorable for tumor growth and metastasis. Traditional cancer treatments, such as chemotherapy and radiation therapy, can be effective at killing tumor cells. However, these treatments can also damage healthy cells, and they often lead to the recurrence of the cancer. By targeting the TME, it is possible to disrupt the interactions between tumor cells and the other cells in the microenvironment, preventing tumor growth and metastasis. This targeting is achieved via drugs that target specific molecules. Another approach to targeting the TME is to use cell-based therapies, where engineered immune cells could be used to attack tumor cells. This Special Issue will provide an overview of the tumor microenvironment and the different ways to target it. The Special Issue will also discuss the challenges and opportunities associated with TME-targeted therapy.





cancers



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
X@Cancers_MDPI